Rivaroxaban: FDA and others [Design Issues]

posted by Tricky TAB – Bangladesh, 2022-07-05 06:42 (41 d 02:49 ago) – Posting: # 23105
Views: 358

» It depends on the ‘target’ agency.

Thanks a lot, Helmut!
For taking the time to help me out!

Wanted to perform BE for ASEAN Regions!
2x2x2 would matter anyway for those countries with same sample size as suggested in FDA guideline?

Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post #5[Helmut]

Complete thread:

UA Flag
 Admin contact
22,301 posts in 4,667 threads, 1,585 registered users;
online 3 (0 registered, 3 guests [including 2 identified bots]).
Forum time: Monday 09:31 CEST (Europe/Vienna)

Science… never solves a problem
without creating ten more.    George Bernard Shaw

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz